Bill > HB3421

This bill requires certain health insurance policies and medical assistance programs to cover biomarker testing under specific conditions. The bill defines biomarker testing as an analysis of a patient's tissue, blood, or other biospecimen to detect biomarkers, which are characteristics that indicate normal biological processes, disease conditions, or potential responses to medical treatments. Specifically, insurers must cover biomarker testing when it is supported by FDA-approved test indications, drug approvals, FDA drug label warnings, Medicare coverage determinations, or nationally recognized clinical practice guidelines. The coverage must be provided in a way that minimizes disruptions to patient care, such as reducing the need for multiple biopsies. The bill applies to health insurance policies offered, renewed, or extended after the bill's effective date, and extends to the Oregon Health Plan's coordinated care organizations. The legislation aims to ensure patients have access to advanced diagnostic testing that can help personalize medical treatment based on an individual's specific genetic or molecular characteristics.

Health and Social Services

https://olis.oregonlegislature.gov/liz/2025R1/Measures/Overview/HB3421